daunorubicin has been researched along with Hemoglobinuria, Paroxysmal in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Fu, R; Li, L; Liu, C; Liu, H; Liu, Z; Shao, Z; Wang, H; Zhao, X | 1 |
| Füreder, W; Gleixner, K; Grünberger, B; Hoermann, G; Kornauth, C; Schwarzinger, I; Sperr, WR; Thalhammer, R; Valent, P | 1 |
| Bai, J; Cao, YR; Cui, ZZ; Fu, R; He, GS; Jia, HR; Liu, H; Qin, TJ; Shao, ZH; Shi, J; Sun, J; Tu, HF; Wu, YH; Yang, TY; Zhao, MF | 1 |
3 other study(ies) available for daunorubicin and Hemoglobinuria, Paroxysmal
| Article | Year |
|---|---|
Clinical observation of low-dose combination chemotherapy in refractory/recurrent paroxysmal nocturnal hemoglobinuria patients: A single-center retrospective analysis.
Topics: Adult; Aged; Cytarabine; Daunorubicin; Drug Resistance; Drug Therapy, Combination; Female; Glucocorticoids; Hemoglobinuria, Paroxysmal; Humans; Male; Methylprednisolone; Middle Aged; Retrospective Studies; Survival Rate | 2022 |
Major response of PNH to an AML chemotherapy protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Cytarabine; Daunorubicin; Hemoglobinuria, Paroxysmal; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 2018 |
[Preliminary study of DA or HA regimen chemotherapy for the treatment of refractory and relapsed paroxysmal nocturnal hemoglobinuria].
Topics: Adolescent; Adult; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Glycosylphosphatidylinositols; Harringtonines; Hemoglobinuria, Paroxysmal; Humans; Male | 2004 |